Micron Makes the $1 Trillion Club a Little More Crowded

Micron crossed $1 trillion in market value as AI-driven high-bandwidth memory demand, long-term contracts through 2029, and supply constraints continue to support pricing and earnings power. Eli Lilly posted encouraging Phase 1B data for VERVE-102, with LDL cholesterol reduced by up to 62% and effects lasting 18 months, while also deploying up to $4 billion across three vaccine developers. Zscaler beat Q3 estimates on revenue and EPS, but the stock fell 30% after management cut full-year free cash flow margin guidance from 26.8% to 23% and flagged heavier AI capex.

Analysis

Micron’s re-rate is less about a single upbeat analyst note than a regime shift in bargaining power. When a supplier can lock a meaningful share of output under multi-year contracts while still unable to meet demand, the market stops valuing earnings as cyclical peak earnings and starts capitalizing a quasi-infrastructure annuity. The second-order effect is that every hyperscaler and GPU vendor is now effectively underwriting Micron’s capex cycle, which should compress future competitive intensity in the short run but also makes the eventual inflection more violent once inventory normalization arrives.

The key mistake in consensus thinking is treating this as a pure AI beneficiary story rather than a supply-constrained pricing story with a long lead time. New capacity won’t matter until late in the cycle, so the risk is not near-term replacement demand but customer design substitution: model compression, memory pooling, and architecture changes that reduce per-accelerator memory intensity. That means the upside can persist for months, but the stock is now vulnerable to any hint that procurement teams are pulling forward spend less aggressively or that contract pricing has plateaued before 2028 supply arrives.

Eli Lilly’s optionality is being underwritten by a cash engine that many are still mentally anchoring to a single franchise. The real insight is capital allocation asymmetry: by buying early-stage shots on goal in areas with high regulatory optionality, Lilly is extending its growth duration well beyond the market’s current terminal assumptions. The danger is not execution collapse, but mean reversion in investor expectations if one or two of these bets disappoint while the core franchise slows; however, that is a years-out risk, not a near-term one.

Zscaler is the clearest example of a stock where the move is likely overdone relative to fundamentals, but underdone in terms of strategic uncertainty. The near-term hit is margin compression from AI infrastructure spend and a sales transition, yet cybersecurity remains one of the last categories CIOs cut, so the business itself is not impaired. The bigger question is whether AI changes the competitive topology of security, and that is a multi-quarter, maybe multi-year issue; for now, the selloff looks like factor de-risking rather than a thesis break.

Key Decisions for Investors

• Long MU into the next 1-3 months on the view that pricing power remains intact until customers visibly flinch; use a trailing stop if commentary shifts to contract renegotiation or delayed AI deployment.
• Sell out-of-the-money MU calls or run a covered-call overlay against existing long exposure; implied volatility should stay elevated, but the stock is now exposed to any supply-capacity or design-substitution headline over the next 2-4 quarters.
• Initiate a pair trade: long LLY / short ZS for a 6-12 month horizon, expressing preference for visible capital-allocation compounding over software names facing AI-driven margin pressure and multiple compression.
• Use weakness in ZS to leg into a small starter long only if it trades closer to the low end of its historical sales multiple range; otherwise avoid catching the knife until the market stabilizes around capex and sales-force turnover.
• For biotech growth exposure, prefer LLY on any pullback over chasing the move in MU; the risk/reward is better because Lilly’s upside is driven by optionality breadth, not a single supply-demand cycle.